Abstract:
Background. The blastic crisis of chronic myeloid leukemia (CML-BC) is usually the final
phase of the disease, in which the percentage of the young, often undifferentiated cells, known as
blastocytes gets above 20%. Nowadays, in the era of the therapy with Tyrosine Kinase
Inhibitors, the transformation from CML to CML-BC occurs much later and more rarely.